Morphine
Articles · Medicine Compliance Aid Stability · Lactation Safety Information · Published , updated
73572009
Articles
19th December 2019
What naloxone doses should be used in adults to urgently reverse the effects of opioids?
The opioid antagonist, naloxone, is a highly effective antidote the use of which is potentially life-saving. The drug has a role in a wide range… Buprenorphine Diamorphine Emergency medicine and urgent care Fentanyl Medicines Safety Methadone Morphine Naloxone Oxycodone Palliative and End of Life Care Pethidine Q&A
20th December 2018
Which opioids can be used in renal impairment?
Opioids are used in a wide variety of clinical settings and are well established for the treatment of both acute and chronic pain. Renal impairment… Alfentanil Anaesthesia and pain Buprenorphine Codeine Diamorphine Dihydrocodeine Fentanyl Hydromorphone Methadone Morphine Oxycodone Pethidine Q&A Renal and urologic disorders Tramadol
20th December 2018
What is the risk of interaction between opioids and monoamine oxidase inhibitors (MAOIs)?
This article considers the risks of interaction between opioids and monoamine oxidase inhibitors. The use of MAOIs with opioids is contraindicated or cautioned by manufacturers.… Drug interactions Isocarboxazid Linezolid Mental Health Mental health and illness Methylthioninium chloride Moclobemide Morphine Phenelzine Q&A Rasagiline Selegiline Tranylcypromine
18th October 2018
How should medicines be dosed in children who are obese?
Obesity results in physiological changes that can affect the volume of distribution and the clearance of drugs. The extent of these changes is variable and… Aciclovir Aminophylline Benzylpenicillin Carbamazepine Clindamycin Enoxaparin Esomeprazole Gentamicin Heparin Ibuprofen Metronidazole Morphine Omeprazole Ondansetron Paediatric and neonatal medicine Paracetamol Phenobarbital Phenobarbital sodium Phenoxymethylpenicillin Phenytoin Phenytoin sodium Prednisolone Q&A Ranitidine Theophylline Tobramycin Vancomycin
19th December 2017
How should conversion from oral morphine to fentanyl patches be carried out?
This updated Medicines Q&A considers the factors which need to be considered when converting patients from oral morphine to fentanyl patches. Explicit guidance on… Fentanyl Medicines Safety Morphine Palliative and End of Life Care Q&A
12th October 2016
What are the equivalent doses of oral morphine to other oral opioids when used as analgesics in adult palliative care?
Morphine is generally the strong opioid of choice for treating moderate to severe cancer pain and a common question is how to convert a dose… Anaesthesia and pain Buprenorphine Codeine Dihydrocodeine Hydromorphone Morphine Oxycodone Palliative and End of Life Care Q&A Tapentadol Tramadol
30th November 2015
Who can supply or administer Controlled Drugs under the terms of a Patient Group Direction and under what circumstances?
The use of controlled drugs is regulated under the Misuse of Drugs Act 1971 and the Misuse of Drugs Regulations 2001. Not all professions listed… Diamorphine Ketamine Medicines Safety Midazolam Morphine Patient Group Directions Regulatory Advice System Safety Tramadol
16th October 2014
Can opioids be used for pain relief during pregnancy?
There are no specific guidelines for the treatment of pain in pregnancy. Not all analgesics are suitable for use during or at certain stages of… Anaesthesia and pain Codeine Dihydrocodeine Morphine Obstetrics and gynaecology Oxycodone Q&A Tapentadol Tramadol
20th May 2012
Safety in Lactation: Opioid analgesics
The evidence relating to the safe use of opioid analgesics in breastfeeding mothers is very variable between individual drugs. This group of drugs presents a… Buprenorphine Codeine Diamorphine Dihydrocodeine Dipipanone + Cyclizine Fentanyl Hydromorphone Meptazinol Methadone Morphine Oxycodone Papaveretum Pentazocine Pethidine Tapentadol Tramadol
25th March 2011
ARCHIVED NPSA Signal – Intravenous morphine administration in neonatal units – March 2011
Key risks emerging from the review of serious incidents reported by the NHS to its National Reporting and Learning System (NRLS) were shared in in… Medicines Safety Morphine Paediatric and neonatal medicineMedicine Compliance Aid Stability
Zomorph · Archimedes Pharma UK Ltd
Archimedes Pharma UK Ltd
Zomorph
Capsules m/r - various strengths
A2 · Amber 2 · No stability data is available, the manufacturer does not, or cannot recommend use in CAs but there are no theoretical concerns with the product.
Protect from moisture
Protect from heat
Protect from moisture and heat.
11th May 2015
Sevredol · Napp Pharmaceuticals Ltd
Napp Pharmaceuticals Ltd
Sevredol
Tablets f/c - various strengths
A3 · Amber 3 · No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Airtight container
Protect from light
Airtight container and protect from light.
11th May 2015
Filnarine SR · Teva Pharmaceuticals Ltd
Teva Pharmaceuticals Ltd
Filnarine SR
Tablets f/c, m/r various strengths
A3 · Amber 3 · No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
No special precautions for storage
No special precautions for storage.
11th May 2015
Morphgesic SR · Amdipharm Mercury Co Ltd
Amdipharm Mercury Co Ltd
Morphgesic SR
Tablets f/c, m/r various strengths
A2 · Amber 2 · No stability data is available, the manufacturer does not, or cannot recommend use in CAs but there are no theoretical concerns with the product.
Airtight container
Protect from light
Airtight container and protect from light.
11th May 2015
MST Continus · Napp Pharmaceuticals Ltd
Napp Pharmaceuticals Ltd
MST Continus
Tablets f/c, m/r various strengths
A3 · Amber 3 · No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Airtight container
Protect from light
Airtight container and protect from light
11th May 2015
MXL · Napp Pharmaceuticals Ltd
Napp Pharmaceuticals Ltd
MXL
Capsules m/r - various strengths
A2 · Amber 2 · No stability data is available, the manufacturer does not, or cannot recommend use in CAs but there are no theoretical concerns with the product.
No special precautions for storage
No special precautions for storage
11th May 2015
Lactation Safety Information
Except for low dose, immediate release oral formulations
Except for low dose, immediate release oral formulations
Other appropriate analgesic
Significant published evidence of use in breastfeeding
Small amounts in breast milk
Used in full-term neonates from birth
Infant monitoring advised, especially in young infants (see summary)
Low dose, immediate release oral formulations
Low dose, immediate release oral formulations
Significant published evidence of use in breastfeeding
Small amounts in breast milk
Applies to short term, low dose (up to 10mg 4-hourly) oral solutions (e.g. Oramorph) and tablets
Although adverse effects in infant are not likely infant monitoring advised in young infants (see summary)